research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
2 SO3 + RCH2OH → RCH2OSO2−O−SO3H RCH2OSO2−O−SO3H → RCH2OSO3H + SO3 Several million tons of fatty acid sulfates are produced in this way annually. The most common example is sodium dodecylsulfate (SDS) derived from lauryl alcohol.
=== Bromine halides === The halogens form many binary, diamagnetic interhalogen compounds with stoichiometries XY, XY3, XY5, and XY7 (where X is heavier than Y), and bromine is no exception. Bromine forms a monofluoride and monochloride, as well as a trifluoride and pentafluoride. Some cationic and anionic derivatives are also characterised, such as BrF2−, BrCl2−, BrF2+, BrF4+, and BrF6+. Apart from these, some pseudohalides are also known, such as cyanogen bromide (BrCN), bromine thiocyanate (BrSCN), and bromine azide (BrN3). The pale-brown bromine monofluoride (BrF) is unstable at room temperature, disproportionating quickly and irreversibly into bromine, bromine trifluoride, and bromine pentafluoride. It thus cannot be obtained pure. It may be synthesised by the direct reaction of the elements, or by the comproportionation of bromine and bromine trifluoride at high temperatures. Bromine monochloride (BrCl), a red-brown gas, quite readily dissociates reversibly into bromine and chlorine at room temperature and thus also cannot be obtained pure, though it can be made by the reversible direct reaction of its elements in the gas phase or in carbon tetrachloride. Bromine monofluoride in ethanol readily leads to the monobromination of the aromatic compounds PhX (para-bromination occurs for X = Me, But, OMe, Br; meta-bromination occurs for the deactivating X = -CO2Et, –CHO, -NO2); this is due to heterolytic fission of the Br–F bond, leading to rapid electrophilic bromination by Br+. At room temperature, bromine trifluoride (BrF3) is a straw-coloured liquid.
== External links == Antibodies bind to conformational shapes on the surfaces of antigens (Janeway Immunobiology Section 3.8) Antigens can bind in pockets or grooves, or on extended surfaces in the binding sites of antibodies (Janeway Immunobiology Figure 3.8)
Sources: en.wikipedia.org
Furthermore, the judge stated that the obligation of the public power, especially in health, must always be based in the preservation of the public good, and that it is not agreeable to any possibility that could create risks and turn back from the principle of precaution. The city government appealed the decision and had, by the start of March, again been denied the authorization to distribute the medicine that had already been deemed ineffective and harmful in the public sphere. At the beginning of May, the base allied with Melo in the Municipal Chamber approved a proposal that permitted the free distribution of medication for the supposed treatment of COVID-19 that had been released by the health ministry. The project was seen as a way to attempt to circumvent the court's decision.
=== Advantage === Komagataella is able to grow on simple, inexpensive medium, with high growth rate. Komagataella can grow in either shake flasks or a fermenter, which makes it suitable for both small- and large-scale production. Komagataella has two alcohol oxidase genes, Aox1 and Aox2, which include strongly inducible promoters. These two genes allow Komagataella to use methanol as a carbon and energy source. The AOX promoters are induced by methanol, and repressed by glucose. Usually, the gene for the desired protein is introduced under the control of the Aox1 promoter, which means that protein production can be induced by the addition of methanol on medium. After several researches, scientists found that the promoter derived from AOX1 gene in Komagataella is extremely suitable to control the expression of foreign genes, which had been transformed into the Komagataella genome, producing heterologous proteins. With a key trait, Komagataella can grow with extremely high cell density on the culture. This feature is compatible with heterologous protein expression, giving higher yields of production. Komagataella has a well-developed secretory pathway involving the Endoplasmic reticulum and a stacked Golgi apparatus, which is more similar to those of higher eukaryotes to that of Saccharomyces cerevisiae. This enables the efficient folding and post-translational modification of heterologous proteins, including the formation of disulfide bonds and glycosylation.
=== Hydrogen nuclear magnetic resonance === Hydrogen nuclear magnetic resonance (2HNMR) is a technique that uses an external magnetic field and deuterium to replace the ordinary form of hydrogen. The ordinary form of hydrogen refers to the elemental form of hydrogen with a molecular weight of approximately 1 g/mol. It contains only one proton and has no neutrons. Deuterium is the isotope form of hydrogen which has a heavier mass compared to ordinary hydrogen. It contains one proton and neutron and has a molecular weight of approximately 2 g/mol. This technique can be used to investigate motions of acyl chains in lipids. It measures carbon and deuterium interactions and the mobility of these interactions within various regions of the lipid and also determines order parameters. The process involves using quadrupole signaling properties for examining lamellar versus non–lamellar phases as well. An external magnetic field monitors the alignment of paramagnetic compounds and uses changes in the positive or negative magnetic spin values to detect these changes.
Regarded as a founder of CJNG, Don Rodo was vital to the cartel's money laundering and property purchasing operations, reportedly also working alongside CJNG notary public offices in Ciudad Guzmán and Autlán de Navarro to manage changes of ownership of the properties he purchased for El Mencho. In February 2026, it was reported that Abraham was still "in the hands of Mexican authorities" since his February 2025 arrest. On 27 April 2026 Mexican special forces arrested Audias Flores Silva, who is considered a potential successor to "El Mencho", leading the El Jalisco cartel. The Mexican Navy confirmed that the operation to arrest Silva resulted from 19 months of surveillance and also involved more than 500 personnel, six helicopters, and intelligence and reconnaissance aircraft. According to Mexican Secretary of the Navy the operation had in fact started in October 2024 “when the Mexican Navy activated intelligence efforts focused on a priority target (Flores Silva) linked to one of the country’s main criminal organizations (the CJNG). From that moment on, a discreet and sustained systematic follow-up was carried out, based on field intelligence, intelligence gathering, and international cooperation.”
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}&{\frac {\beta }{\gamma }}\leq 1\Rightarrow \lim _{t\to +\infty }I(t)=0,\\[6pt]&{\frac {\beta }{\gamma }}>1\Rightarrow \lim _{t\to +\infty }I(t)=\left(1-{\frac {\gamma }{\beta }}\right)N.\end{aligned}}}
From 2018 to 2023, Sen served as an Indiana University Distinguished Professor. At Indiana University, he directed the Indiana Center for Regenerative Medicine and Engineering (ICRME) and held the J. Stanley Battersby Chair as Distinguished Professor of Surgery. He also served as Associate Dean of Research and Associate Vice President of Research. In 2020, Sen was awarded the Bicentennial Medal by the Indiana University President's Office. In 2021, Sen was elected as a Lifetime Fellow of the National Academy of Inventors. He currently serves as Editor-in-Chief of Antioxidants & Redox Signaling and Advances in Wound Care. In March 2026, the American Diabetes Association announced Sen as winner of the 2026 Roger E Pecoraro award. Sen is widely recognized for co-inventing tissue nanotransfection, a technology enabling in vivo tissue reprogramming. His team also identified vasculogenic fibroblasts in humans. His research also spans electroceutical approaches to infection management and the role of tocotrienol forms of natural vitamin E. Sen served as the principal investigator for the NIH Diabetic Foot Consortium TEWL study. The study recommended revising the FDA definition of wound closure to include restoration of skin barrier function, as wounds with high transepidermal water loss (TEWL) were more likely to recur. Sen has an H-index of 125.
Let us imagine how many people would die if war breaks out. There are 2.7 billion people in the world, and a third could be lost. If it is a little higher it could be half ... I say that if the worst came to the worst and one-half dies, there will still be one-half left, but imperialism would be razed to the ground and the whole world would become socialist. After a few years there would be 2.7 billion people again.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.